In a bid to enhance its global position in T-cell therapies, BioNTech has agreed to pay US$67 M for Neon Therapeutics, which is developing novel neoantigen-based T-cell therapies. The deal gives BioNTech access to Neon’s personal and precision therapies including NEO-PTC-01, a non-engineered product that leverages peripheral blood mononuclear cells to specifically target the most therapeutically relevant neoantigens from each patient’s tumour. BioNTech also gains NEO-STC-01 which targets shared neoantigens in patients with pancreatic cancer.